Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 21:56 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 17,056 | $60.36 | $1,029,500.16 |
DisclosureSEC source: 0001258693-26-000019 · wk-form4_1788990967.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,902 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2026 Filed Sep 2, 2026 23:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,427 | $61.58 | $211,034.66 |
DisclosureSEC source: 0001258693-26-000017 · wk-form4_1788393451.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,958 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 23:57 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,862 | $60.74 | $173,837.88 |
DisclosureSEC source: 0001258693-26-000017 · wk-form4_1788393451.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,385 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 16,198 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · derivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 16,198 shares Expires 2028-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 378 | $55.91 | $21,135.49 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 133,215 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.82 to $56.085. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 622 | $55.54 | $34,545.88 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 133,593 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F8 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 244 | $55.96 | $13,655.22 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 133,215 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.81 to $56.18. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 756 | $55.52 | $41,970.10 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 133,459 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,415 | $55.93 | $246,935.37 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,247 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.77 to $56.13. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,783 | $55.52 | $654,133.25 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 457,662 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.77 to $55.765. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 27, 2026 Filed Jul 28, 2026 20:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 16,198 | $2.03 | $32,881.94 |
DisclosureSEC source: 0001258693-26-000015 · wk-form4_1785269436.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 469,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 191 | $56.27 | $10,746.81 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 9 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 134,215 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F12 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F10 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 602 | $55.30 | $33,288.79 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 134,406 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F11 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F10 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 207 | $54.22 | $11,223.95 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 135,008 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F10 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 332 | $55.99 | $18,589.68 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 134,215 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.88 to $56.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 356 | $55.23 | $19,660.46 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 134,547 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.80 to $55.51. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 312 | $54.35 | $16,955.64 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 134,903 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $53.77 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,417 | $56.12 | $360,128.46 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,466 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $55.815 to $56.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,137 | $55.27 | $504,956.31 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 458,883 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.755 to $55.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 26, 2026 Filed Jun 26, 2026 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,683 | $54.28 | $362,719.83 |
DisclosureSEC source: 0001258693-26-000013 · wk-form4_1782514151.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 468,020 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $53.755 to $54.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:28 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001258693-26-000011 · form4-06242026_100648.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 225 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option is fully vested and exercisable. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,000 | $52.50 | $52,500.00 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 135,215 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,000 | $52.50 | $52,500.00 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 135,215 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. F2 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 22,236 | $52.50 | $1,167,390.00 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,703 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 225 | $52.51 | $11,814.75 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 496,939 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026. Read SEC document |
| June 18, 2026 Filed Jun 19, 2026 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 225 | $1.79 | $402.75 |
DisclosureSEC source: 0001258693-26-000010 · wk-form4_1781827692.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 497,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2026 Filed Apr 13, 2026 20:55 UTC | LeonaBio, Inc. LONA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001258693-26-000008 · form4-04132026_080428.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-04-08 F1 · derivative.exercise_date: The shares subject to the option shall be scheduled to vest monthly over a term of 24 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,685 | $59.32 | $218,594.20 |
DisclosureSEC source: 0001258693-26-000006 · wk-form4_1773264290.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,939 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,531 | $61.98 | $156,871.38 |
DisclosureSEC source: 0001258693-26-000004 · wk-form4_1772500062.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,624 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,863 | $61.98 | $177,448.74 |
DisclosureSEC source: 0001258693-26-000004 · wk-form4_1772500062.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,155 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 175,698 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001258693-26-000004 · wk-form4_1772500062.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,698 Underlying: Common Stock · 175,698 shares Expires 2036-02-26 F5 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 105,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001258693-26-000004 · wk-form4_1772500062.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,018 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| January 14, 2026 Filed Jan 16, 2026 22:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001258693-26-000002 · wk-form4_1768601425.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,908 F1 · shares: The reported transaction involves the Reporting Person's transfer of shares to an irrevocable trust for estate planning purposes. The Reporting Person no longer has a pecuniary interest in the shares and therefore disclaims beneficial ownership. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:26 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 7,356 | $32.41 | $238,407.96 |
DisclosureSEC source: 0001258693-25-000006 · wk-form4_1757535964.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,908 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 3,420 | $31.56 | $107,935.20 |
DisclosureSEC source: 0001258693-25-000004 · wk-form4_1757016596.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,264 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 4,563 | $31.56 | $144,008.28 |
DisclosureSEC source: 0001258693-25-000004 · wk-form4_1757016596.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,684 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:09 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,857 | $31.56 | $90,166.92 |
DisclosureSEC source: 0001258693-25-000004 · wk-form4_1757016596.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 516,247 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. F2 · balance_after: Includes 329 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 21:32 UTC | LeonaBio, Inc. ATHA · Entity 1487 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-015431 · form4-06032025_090653.xml · derivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2035-05-29 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) May 30, 2026, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 11:38 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 4,752 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001649094-25-000047 · wk-form4_1744025879.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,360 Underlying: Common Stock · 4,752 shares Expires 2031-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 11:38 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,781 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-25-000047 · wk-form4_1744025879.xml · derivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,936 Underlying: Common Stock · 15,781 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 11:38 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 4,752 | $20.93 | $99,459.36 |
DisclosureSEC source: 0001649094-25-000047 · wk-form4_1744025879.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2025 Filed Apr 7, 2025 11:38 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,781 | $5.35 | $84,428.35 |
DisclosureSEC source: 0001649094-25-000047 · wk-form4_1744025879.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2025 Filed Mar 4, 2025 02:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 57,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-25-000037 · wk-form4_1741054251.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 508,239 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 7,984 | $72.10 | $575,646.40 |
DisclosureSEC source: 0001649094-25-000037 · wk-form4_1741054251.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 498,242 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 2,013 | $73.02 | $146,989.26 |
DisclosureSEC source: 0001649094-25-000037 · wk-form4_1741054251.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,226 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 193,431 | $0.00 Strike: $74.22 | $0.00 |
DisclosureSEC source: 0001649094-25-000037 · wk-form4_1741054251.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,431 Underlying: Common Stock · 193,431 shares Expires 2035-02-26 F5 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 154 | $93.60 | $14,414.09 |
DisclosureSEC source: 0001649094-24-000121 · wk-form4_1733865045.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 136,215 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $93.355 to $93.72. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,029 | $92.03 | $94,700.93 |
DisclosureSEC source: 0001649094-24-000121 · wk-form4_1733865045.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 136,369 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.715 to $92.63. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F6 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 222 | $93.10 | $20,668.20 |
DisclosureSEC source: 0001649094-24-000121 · wk-form4_1733865045.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 136,215 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $92.80 to $93.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.